Prostate Cancer - Results from #1420

Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. January 29, 2024

Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial. January 29, 2024

The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer. January 29, 2024

Interactive training workshop to improve prostate mpMRI knowledge: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. January 26, 2024

Functional Outcomes After Localized Prostate Cancer Treatment. January 26, 2024

Impact of PSMA PET on Prostate Cancer Management. January 26, 2024

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). January 26, 2024

An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223. January 26, 2024

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. January 26, 2024

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. January 26, 2024

The association of body mass index with tumor aggression among men undergoing radical prostatectomy. January 25, 2024

Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study. January 25, 2024

Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making. January 25, 2024

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). January 25, 2024

Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study. January 25, 2024

Physician Perception of Grade Group 1 Prostate Cancer. January 25, 2024

First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients. January 24, 2024

UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. January 24, 2024

Cardiovascular Disease and Chronic Pulmonary Disease Increase the Risk of Short-Term Major Postoperative Complications after Robotic-Assisted Radical Prostatectomy. January 24, 2024

Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. January 24, 2024

Page 72 of 1435